Trials / Terminated
TerminatedNCT00365898
Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain
A Study of the Efficacy and Safety of 8 Mg Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 380 (planned)
- Sponsor
- Purdue Pharma LP · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of 8 mg Hydromorphone Hydrochloride Extended-Release.
Detailed description
The primary efficacy objective of this study is to compare the time to emergence of inadequate analgesia of 8 mg Hydromorphone Hydrochloride Extended-Release taken once every 24 hours versus placebo in the treatment of patients with persistent pain who require an opioid medication for control of their pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydromorphone Hydrochloride Extended-Release |
Timeline
- Start date
- 2005-07-01
- Completion
- 2005-07-01
- First posted
- 2006-08-18
- Last updated
- 2006-08-18
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00365898. Inclusion in this directory is not an endorsement.